Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus
mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF
status from circulating DNA analysis.
Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.